Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Connection

Janet Rader to Aged, 80 and over

This is a "connection" page, showing publications Janet Rader has written about Aged, 80 and over.

 
Connection Strength
 
 
 
0.553
 
  1. Nugent EK, Case AS, Hoff JT, Zighelboim I, DeWitt LL, Trinkhaus K, Mutch DG, Thaker PH, Massad LS, Rader JS. Chemoradiation in locally advanced cervical carcinoma: an analysis of cisplatin dosing and other clinical prognostic factors. Gynecol Oncol. 2010 Mar; 116(3):438-41.
    View in: PubMed
    Score: 0.051
  2. Wright JD, Gibb RK, Geevarghese S, Powell MA, Herzog TJ, Mutch DG, Grigsby PW, Gao F, Trinkaus KM, Rader JS. Cervical carcinoma in the elderly: an analysis of patterns of care and outcome. Cancer. 2005 Jan 01; 103(1):85-91.
    View in: PubMed
    Score: 0.037
  3. Summey RM, Gornstein E, Decker B, Dougherty KC, Rader JS, Hopp E. Landscape of potential germline pathogenic variants in select cancer susceptibility genes in patients with adult-type ovarian granulosa cell tumors. Cancer Med. 2024 Jun; 13(12):e7340.
    View in: PubMed
    Score: 0.035
  4. Moh M, Puzyrenko A, Summey R, Rader JS, Herrera Cano GE, Gavina JV, Rui H, Sun Y, Hopp E. Clinicopathologic Characteristics of a Single-institution Cohort of Ovarian Adult Granulosa Cell Tumors, With Biomarker and Therapeutic Implications Utilizing the Detection of Androgen, Estrogen, and Progesterone Hormone Receptor Expression by Immunohistochemistry. Int J Gynecol Pathol. 2024 Sep 01; 43(5):527-534.
    View in: PubMed
    Score: 0.035
  5. Rader JS, Clarke-Pearson D, Moore M, Carson L, Holloway R, Kao MS, Wiznitzer I, Douglass EC. A phase II study to determine the efficacy and tolerability of intravenous ZD9331 in heavily pretreated patients with ovarian cancer. Gynecol Oncol. 2003 Nov; 91(2):318-25.
    View in: PubMed
    Score: 0.034
  6. Harold JA, Uyar D, Rader JS, Bishop E, Nugent M, Simpson P, Bradley WH. Adipose-only sentinel lymph nodes: a finding during the adaptation of a sentinel lymph node mapping algorithm with indocyanine green in women with endometrial cancer. Int J Gynecol Cancer. 2019 01; 29(1):53-59.
    View in: PubMed
    Score: 0.024
  7. Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, Porta-Pardo E, Gao GF, Plaisier CL, Eddy JA, Ziv E, Culhane AC, Paull EO, Sivakumar IKA, Gentles AJ, Malhotra R, Farshidfar F, Colaprico A, Parker JS, Mose LE, Vo NS, Liu J, Liu Y, Rader J, Dhankani V, Reynolds SM, Bowlby R, Califano A, Cherniack AD, Anastassiou D, Bedognetti D, Mokrab Y, Newman AM, Rao A, Chen K, Krasnitz A, Hu H, Malta TM, Noushmehr H, Pedamallu CS, Bullman S, Ojesina AI, Lamb A, Zhou W, Shen H, Choueiri TK, Weinstein JN, Guinney J, Saltz J, Holt RA, Rabkin CS, Lazar AJ, Serody JS, Demicco EG, Disis ML, Vincent BG, Shmulevich I. The Immune Landscape of Cancer. Immunity. 2018 04 17; 48(4):812-830.e14.
    View in: PubMed
    Score: 0.023
  8. Liapis H, Adler LM, Wick MR, Rader JS. Expression of alpha(v)beta3 integrin is less frequent in ovarian epithelial tumors of low malignant potential in contrast to ovarian carcinomas. Hum Pathol. 1997 Apr; 28(4):443-9.
    View in: PubMed
    Score: 0.021
  9. Divine LM, Kizer NT, Hagemann AR, Pittman ME, Chen L, Powell MA, Mutch DG, Rader JS, Thaker PH. Clinicopathologic characteristics and survival of patients with gynecologic malignancies metastatic to the brain. Gynecol Oncol. 2016 07; 142(1):76-82.
    View in: PubMed
    Score: 0.020
  10. Kharofa J, Morrow N, Kelly T, Rownd J, Paulson E, Rader J, Uyar D, Bradley W, Erickson B. 3-T MRI-based adaptive brachytherapy for cervix cancer: treatment technique and initial clinical outcomes. Brachytherapy. 2014 Jul-Aug; 13(4):319-25.
    View in: PubMed
    Score: 0.018
  11. Liapis H, Crouch EC, Roby J, Rader JS. In situ localization of parathyroid hormone-like protein and mRNA in intraepithelial neoplasia and invasive carcinoma of the uterine cervix. Hum Pathol. 1993 Oct; 24(10):1058-66.
    View in: PubMed
    Score: 0.017
  12. Kizer NT, Thaker PH, Gao F, Zighelboim I, Powell MA, Rader JS, Mutch DG, Grigsby PW. The effects of body mass index on complications and survival outcomes in patients with cervical carcinoma undergoing curative chemoradiation therapy. Cancer. 2011 Mar 01; 117(5):948-56.
    View in: PubMed
    Score: 0.014
  13. Kidd EA, Spencer CR, Huettner PC, Siegel BA, Dehdashti F, Rader JS, Grigsby PW. Cervical cancer histology and tumor differentiation affect 18F-fluorodeoxyglucose uptake. Cancer. 2009 Aug 01; 115(15):3548-54.
    View in: PubMed
    Score: 0.013
  14. Nugent EK, Zighelboim I, Case AS, Gao F, Thaker PH, Rader JS, Mutch DG, Massad LS. The value of perioperative imaging in patients with uterine sarcomas. Gynecol Oncol. 2009 Oct; 115(1):37-40.
    View in: PubMed
    Score: 0.013
  15. Brooks RA, Rader JS, Dehdashti F, Mutch DG, Powell MA, Thaker PH, Siegel BA, Grigsby PW. Surveillance FDG-PET detection of asymptomatic recurrences in patients with cervical cancer. Gynecol Oncol. 2009 Jan; 112(1):104-9.
    View in: PubMed
    Score: 0.012
  16. Herzog TJ, Powell MA, Rader JS, Gibb RK, Lippmann L, Coleman RL, Mutch DG. Phase II evaluation of topotecan and navelbine in patients with recurrent ovarian, fallopian tube or primary peritoneal cancer. Gynecol Oncol. 2008 Dec; 111(3):467-73.
    View in: PubMed
    Score: 0.012
  17. Nguyen TT, Wright JD, Powell MA, Gibb RK, Rader JS, Allsworth JE, Mutch DG. Prognostic factors associated with response in platinum retreatment of platinum-resistant ovarian cancer. Int J Gynecol Cancer. 2008 Nov-Dec; 18(6):1194-9.
    View in: PubMed
    Score: 0.011
  18. Wright JD, Grigsby PW, Rader JS, Mutch DG, Powell MA, Gao F, Gibb RK. Effect of a T0 radical hysterectomy specimen on survival for early stage cervical cancer. Gynecol Oncol. 2007 Nov; 107(2):280-4.
    View in: PubMed
    Score: 0.011
  19. Fayed A, Mutch DG, Rader JS, Gibb RK, Powell MA, Wright JD, Elnaqa I, Zoberi I, Grigsby PW. Comparison of high-dose-rate and low-dose-rate brachytherapy in the treatment of endometrial carcinoma. Int J Radiat Oncol Biol Phys. 2007 Feb 01; 67(2):480-4.
    View in: PubMed
    Score: 0.010
  20. McCourt CK, Mutch DG, Gibb RK, Rader JS, Goodfellow PJ, Trinkaus K, Powell MA. Body mass index: relationship to clinical, pathologic and features of microsatellite instability in endometrial cancer. Gynecol Oncol. 2007 Mar; 104(3):535-9.
    View in: PubMed
    Score: 0.010
  21. Herzog TJ, Powell MA, Rader JS, Gibb R, Mutch DG. Phase II evaluation of a 3-day infusion of topotecan in patients with recurrent ovarian or primary peritoneal cancer. Gynecol Oncol. 2006 Nov; 103(2):637-41.
    View in: PubMed
    Score: 0.010
  22. Gossner G, Coleman RL, Mutch DG, Horowitz NS, Rader JS, Gibb RK, Powell MA, Herzog TJ. CA-125 response in patients with recurrent ovarian or primary peritoneal cancer treated with pegylated liposomal doxorubicin or topotecan. Gynecol Oncol. 2006 Oct; 103(1):212-8.
    View in: PubMed
    Score: 0.010
  23. Lewin SN, Buttin BM, Powell MA, Gibb RK, Rader JS, Mutch DG, Herzog TJ. Resource utilization for ovarian cancer patients at the end of life: how much is too much? Gynecol Oncol. 2005 Nov; 99(2):261-6.
    View in: PubMed
    Score: 0.010
  24. Wright JD, Powell MA, Mutch DG, Rader JS, Gibb RK, Gao F, Herzog TJ. Relationship of ovarian neoplasms and body mass index. J Reprod Med. 2005 Aug; 50(8):595-602.
    View in: PubMed
    Score: 0.010
  25. Wright JD, Rosenblum K, Huettner PC, Mutch DG, Rader JS, Powell MA, Gibb RK. Cervical sarcomas: an analysis of incidence and outcome. Gynecol Oncol. 2005 Nov; 99(2):348-51.
    View in: PubMed
    Score: 0.010
  26. Grigsby PW, Singh AK, Siegel BA, Dehdashti F, Rader J, Zoberi I. Lymph node control in cervical cancer. Int J Radiat Oncol Biol Phys. 2004 Jul 01; 59(3):706-12.
    View in: PubMed
    Score: 0.009
  27. Buttin BM, Powell MA, Mutch DG, Babb SA, Huettner PC, Edmonston TB, Herzog TJ, Rader JS, Gibb RK, Whelan AJ, Goodfellow PJ. Penetrance and expressivity of MSH6 germline mutations in seven kindreds not ascertained by family history. Am J Hum Genet. 2004 Jun; 74(6):1262-9.
    View in: PubMed
    Score: 0.009
  28. Wright JD, Powell MA, Mutch DG, Rader JS, Gibb RK, Huettner PC, Herzog TJ. Synchronous ovarian metastases at the time of laparotomy for colon cancer. Gynecol Oncol. 2004 Mar; 92(3):851-5.
    View in: PubMed
    Score: 0.009
  29. Ivanovich J, Babb S, Goodfellow P, Mutch D, Herzog T, Rader J, Whelan A. Evaluation of the family history collection process and the accuracy of cancer reporting among a series of women with endometrial cancer. Clin Cancer Res. 2002 Jun; 8(6):1849-56.
    View in: PubMed
    Score: 0.008
  30. Powell MA, Mutch DG, Rader JS, Herzog TJ, Huang TH, Goodfellow PJ. Ribosomal DNA methylation in patients with endometrial carcinoma: an independent prognostic marker. Cancer. 2002 Jun 01; 94(11):2941-52.
    View in: PubMed
    Score: 0.008
  31. Bloss JD, Blessing JA, Behrens BC, Mannel RS, Rader JS, Sood AK, Markman M, Benda J. Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol. 2002 Apr 01; 20(7):1832-7.
    View in: PubMed
    Score: 0.008
  32. Cohn DE, Dehdashti F, Gibb RK, Mutch DG, Rader JS, Siegel BA, Herzog TJ. Prospective evaluation of positron emission tomography for the detection of groin node metastases from vulvar cancer. Gynecol Oncol. 2002 Apr; 85(1):179-84.
    View in: PubMed
    Score: 0.008
  33. Plaxe SC, Blessing JA, Husseinzadeh N, Webster KD, Rader JS, Dunton CJ. Phase II trial of pyrazoloacridine in patients with persistent or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol. 2002 Feb; 84(2):241-4.
    View in: PubMed
    Score: 0.007
  34. Buttin BM, Herzog TJ, Powell MA, Rader JS, Mutch DG. Epithelial ovarian tumors of low malignant potential: the role of microinvasion. Obstet Gynecol. 2002 Jan; 99(1):11-7.
    View in: PubMed
    Score: 0.007
  35. Cohn DE, Mutch DG, Rader JS, Farrell M, Awantang R, Herzog TJ. Factors predicting subcutaneous implanted central venous port function: the relationship between catheter tip location and port failure in patients with gynecologic malignancies. Gynecol Oncol. 2001 Dec; 83(3):533-6.
    View in: PubMed
    Score: 0.007
  36. Kowalski LD, Mutch DG, Herzog TJ, Rader JS, Goodfellow PJ. Mutational analysis of MLH1 and MSH2 in 25 prospectively-acquired RER+ endometrial cancers. Genes Chromosomes Cancer. 1997 Mar; 18(3):219-27.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.